Vertex reports results from Phase IIb AMPLIFIED trial for AMKD

Vertex Pharmaceuticals has reported positive data from its Phase IIb AMPLIFIED trial evaluating inaxaplin in individuals with AMKD. AMKD is caused by two APOL1 gene variants and can lead to progressive kidney damage. Credit: sasirin pamai / Shutterstock.com. Vertex Pharmaceuticals has reported positive data from its Phase IIb AMPLIFIED trial evaluating inaxaplin in individuals with APOL1-mediated kidney disease (AMKD), including those with modest proteinuria and people diagnosed with type 2 diabetes (T2D). The AMPLIFIED study evaluated a 45mg once-daily dose of inaxaplin alongside optimised standard of care. It included 41 people in two cohorts. LOA and PTSR Model AVID-200…

Source: Clinical Trials Arena